한글목차

PIVKA II 항원 세계 시장 전망은 병원 및 클리닉 시장에서의 기회로 인해 유망합니다. 세계 PIVKA II 항원 시장은 2025년부터 2031년까지 CAGR 5.6%로 성장할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 간 질환의 유병률 증가, 스크리닝 및 진단 활동의 증가, 바이오마커 검출의 기술 발전의 확대입니다.

• Lucintel의 예측에 따르면, 유형별로는 혈청이 예측 기간 동안 높은 성장세를 보일 것으로 예상됩니다.
• 용도별로는 병원이 예측 기간 동안 높은 성장이 예상됩니다.
• 지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장을 보일 것으로 예상됩니다.

PIVKA II 항원 시장의 전략적 성장 기회

PIVKA II 항원 시장에는 특정 응용 분야에서 다양한 전략적 성장 기회가 있습니다. 이러한 분야는 시장에서의 존재감을 높이고 환자 치료를 개선하는 데 도움이 될 수 있습니다.

• PIVKA II 항원의 현장 검사 확대 PIVKA II 항원의 현장 검사가 확대됨에 따라, 환자들은 보다 편안하고 간편한 방법으로 검사를 받을 수 있게 되었습니다.
• 예방 의료에 집중 : 예방 의료의 일환으로 PIVKA II를 활용하면 간 질환의 조기 진단을 촉진하고, 의료진이 적시에 적절한 조치를 취해 질병 부담을 줄일 수 있습니다.
• 새로운 시장 진출 : 새로운 시장, 특히 간질환 환자 수가 증가하고 있는 국가에서는 PIVKA II 검사를 적용하는 것이 유리합니다. 이러한 시장에 대응하도록 현지화된 제품은 받아들여질 가능성이 높습니다.
• 의료 서비스 제공자와의 협업 : 병원 및 클리닉과의 비즈니스 관계를 발전시킴으로써 PIVKA II 검사를 환자의 정기 검진에 통합하고, 워크플로우를 확장하고, 중요한 검사에 대한 접근성을 확대할 수 있습니다.
• R&D 투자 : R&D에 대한 추가 투자는 PIVKA II의 다른 새로운 용도의 개발을 가능하게 하고, 제품 다양화 및 시장에서의 입지를 강화할 수 있는 새로운 길을 열어줄 것입니다.

이러한 전략적 성장 기회는 PIVKA II 항원 시장 확대 전망과 일치합니다. 이러한 신규 용도 및 공동연구에 집중함으로써 환자 예후 개선, 시장 개척, 간질환 관리 개선의 기회를 제공할 수 있습니다.

PIVKA II 항원 시장의 촉진요인 및 과제

PIVKA II 항원 시장은 기술적, 경제적, 규제적 문제 등 여러 시장 촉진요인 및 과제에 영향을 받습니다. 이러한 요인을 이해하면 이 특수한 환경에서 활동하는 모든 이해관계자가 환경 변화에 적응하는 데 도움이 될 것입니다.

PIVKA II 항원 시장을 이끄는 요인은 다음과 같습니다:

1. 간질환의 증가 : 간염, 간암 등 간질환의 증가 추세는 PIVKA II 검사와 같은 진단약에 긍정적인 영향을 미쳐 시장 전망을 개선하고 있습니다.

2. 기술 혁신 : 새로운 분석 기술은 PIVKA II 검사 결과의 정확도를 향상시킵니다. 이러한 개발은 조기 진단에 접근하고 환자의 결과를 개선하기 위해 필요합니다.

3. 비용 증가에 대한 두려움과 교육의 흐름 : 의료진과 환자들의 간 인식이 높아지면서 PIVKA II 항원 검사의 채택을 촉진하고 있으며, 그 결과 시장 수요와 이용이 증가하고 있습니다.

4. 유리한 가이드라인과 법규 : 유리한 규제 정책은 PIVKA II 검사의 개발 및 시행을 촉진하고 있습니다. 이러한 지원은 시장과 기술에 대한 신뢰도를 높이고 새로운 진보의 채택을 촉진합니다.

5. 협업과 파트너십 : 교육기관, 산업계, 헬스케어 부문의 공동 활동은 새로운 PIVKA II 제품 개발 및 시장에서의 지위 향상을 촉진합니다.

PIVKA II 항원 시장의 과제는 다음과 같습니다:

1. 높은 검사 비용 : PIVKA II 검사 실시와 관련된 비용은 일부 환자들에게 고비용이 될 수 있으며, 이는 특정 인구 집단이나 지리적 지역에서 이 서비스에 대한 접근성을 제한할 수 있습니다.

2. 다른 바이오마커와의 경쟁 : 이미 사용되고 있는 다른 간암 마커의 존재는 PIVKA II의 경쟁상대가 될 수 있으며, PIVKA II의 독창성을 지지하기 위한 지속적인 노력의 필요성을 강조합니다.

3. 신흥 시장의 규제 장애물 : 신흥 시장 진출은 PIVKA II 검사 솔루션의 출시를 지연시키고 시장 기회를 제한할 수 있는 엄격한 규제 노력을 수반할 수 있습니다.

PIVKA II 항원 시장에 긍정적인 영향을 미치는 이러한 모든 촉진요인과 과제들이 상호 작용하고 있음이 분명합니다. 시장 진입 기업들은 기회를 활용하고 문제를 해결함으로써 제품 및 서비스를 개선하고 간 질환 관리의 새로운 표준을 제시할 수 있습니다.

목차

제1장 주요 요약

제2장 세계의 PIVKA II 항원 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 2019년부터 2031년까지 시장 동향과 예측 분석

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 PIVKA II 항원 시장 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 PIVKA II 항원 시장, 유형별
  • 혈청
  • 플라즈마
  • 기타
• 세계의 PIVKA II 항원 시장, 용도별
  • 병원
  • 클리닉
  • 기타

제4장 2019년부터 2031년까지 지역별 시장 동향과 예측 분석

• 지역별 PIVKA II 항원 세계 시장
• 북미의 PIVKA II 항원 시장
• 유럽의 PIVKA II 항원 시장
• 아시아태평양의 PIVKA II 항원 시장
• 기타 지역의 PIVKA II 항원 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 PIVKA II 항원 시장 성장 기회, 유형별
  • 세계의 PIVKA II 항원 시장 성장 기회, 용도별
  • 세계의 PIVKA II 항원 시장 성장 기회, 지역별
• 세계의 PIVKA II 항원 시장 최신 동향
• 전략 분석
  • 신제품 개발
  • 세계의 PIVKA II 항원 시장 능력 확대
  • 세계의 PIVKA II 항원 시장 합병, 인수, 합작투자
  • 인증과 라이선싱

제7장 주요 기업 개요

• FUJIFILM
• LabCorp
• Abbexa
• GenScript
• Eisai

영문목차

The future of the global PIVKA II antigen market looks promising with opportunities in the hospital and clinic markets. The global PIVKA II antigen market is expected to grow with a CAGR of 5.6% from 2025 to 2031. The major drivers for this market are the rising prevalence of liver diseases, increased screening & diagnostic activities, and growing technological advancements in biomarker detection.

• Lucintel forecasts that, within the type category, serum is expected to witness higher growth over the forecast period.
• Within the application category, hospitals are expected to witness higher growth over the forecast period.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period.

Gain Valuable Insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the PIVKA II Antigen Market

The trends prevailing in the PIVKA II antigen market can be defined as PIVKA II antigen market trends that are caused by technological breakthroughs or changes in the delivery of healthcare services. These trends are creating new opportunities and challenges for stakeholders in the market.

• Increased Utilization in Early Detection: The trend of using PIVKA II for the early diagnosis of liver cancer is increasing. With an increase in liver disease awareness, clinicians are employing this biomarker in the screening of patients, allowing for quicker prevention and treatment.
• Technological Advancements in Testing: Advances in various technologies used for the detection of PIVKA II are making testing more sensitive and specific. These newly developed technologies are changing the landscape of tests, which is important for the management of patients and for the plans made for their treatment.
• Regulatory Support and Standardization: The standardization of testing parameters for PIVKA II by regulatory authorities is boosting its acceptance. There is a positive trend in this regard that enhances the trust of both healthcare providers and patients, which in turn promotes the use of such therapies in clinical practice.
• Focus on Personalized Medicine: The trend of personalized medicine is affecting the PIVKA II market as more healthcare providers are using biomarkers to develop aggressive treatment regimens. This strategy contributes to increased efficacy, as patients receive the therapeutics they need rather than those that generally fit the given guidelines.
• Expansion into Emerging Markets: Rising awareness of liver ailments among patients in developing countries is fueling the usage of PIVKA II antigen testing. In this context, manufacturers are targeting these areas due to the market's availability, which has made the purchase and use of these tests easier and more affordable.

These emerging trends are altering the PIVKA II antigen market by improving detection capabilities, increasing regulatory support, and supporting the need for personalized medicine. As stakeholders support these cross-cutting opportunities, the market is poised for expansion and modernization, which will eventually lead to improved patient care in the management of liver cancer.

Recent Developments in the PIVKA II Antigen Market

The PIVKA II antigen market has recently undergone changes that influence its direction. These improvements are fundamental to better diagnosis and patient management systems.

• Enhanced Testing Assays: The emergence of more precise PIVKA II testing assays has raised both the sensitivity and specificity of liver cancer diagnosis. Such improvements are vital for primary cancer detection and timely treatment.
• Inclusion in Clinical Practice Guidelines: Recent changes in clinical practice guidelines have started to include PIVKA II as an additional marker for the diagnosis of liver cancer. This recognition improves its implementation in clinical settings and leads to better clinical outcomes.
• Government Promotions for Awareness: Several governments across the world are seeking to educate people about liver diseases, thereby increasing the demand for PIVKA II testing. These measures are important for identifying diseases at an early stage and reducing their onset.
• Increase in Facilities for Conducting Tests: The number of diagnostic centers providing advanced PIVKA II testing is also increasing to enhance the availability of this diagnostic. This expansion provides wider coverage of critical diagnostic access for patients.
• Cooperative Research: Pharmaceuticals and institutions are conducting joint clinical trials on the potential use of PIVKA II, particularly in clinical settings. This research is important as it is expected to address its use in various clinical applications and strengthen the market.

These key developments are significant in driving the PIVKA II antigen market through improvements in diagnostics, awareness, and the growth of research partnerships. As these developments take shape, the PIVKA II antigen market and patient care are likely to improve.

Strategic Growth Opportunities for PIVKA II Antigen Market

The PIVKA II antigen market has a variety of strategic growth opportunities in selected applications. These areas will enhance market presence and, in turn, improve patient care.

• Expansion of Point-of-Care Testing: The expanding point-of-care testing for the PIVKA II antigen will offer patients more comfortable and simpler methods, thus leading to faster detection of diseases and better health.
• Focus on Preventive Healthcare: Utilizing PIVKA II as one component of preventive healthcare initiatives can encourage early diagnosis of liver diseases, allowing for the timely administration of appropriate measures by health professionals, thereby decreasing the disease burden.
• Expansion into New Markets: New markets, especially in countries with increasing cases of liver disorders, can benefit from the application of PIVKA II testing. Products that are localized to cater to these markets stand a higher chance of being accepted.
• Collaboration with Healthcare Providers: Developing business relationships with hospitals and clinics will help include PIVKA II testing in the regular screening of patients, thereby increasing workflow and broadening access to vital tests.
• Investment in Research and Development: Additional investments in research and development will enable the development of other novel uses of PIVKA II, creating new avenues for product diversification and strengthening market position.

These strategic growth opportunities align with the prospect of broadening the PIVKA II antigen market. Emphasizing these novel applications and collaborations will provide opportunities for better patient outcomes, market development, and improvements in liver disease management.

PIVKA II Antigen Market Driver and Challenges

The PIVKA II antigen market is affected by several drivers and challenges, such as technological, economic, and regulatory issues. An appreciation of these factors helps all stakeholders operating in this particular environment adapt to its changes.

The factors responsible for driving the PIVKA II antigen market include:

1. Growing Incidence of Liver Diseases: The increasing trend in liver diseases, such as hepatitis and liver cancer, is positively impacting diagnostics, such as PIVKA II testing, thereby improving prospects in the market.

2. Technological Innovations: New assay technologies improve the precision of PIVKA II test results. These developments are necessary to address early diagnosis and improve patient outcomes.

3. Fear of Increased Cost and Stream of Education: The elevation of liver health awareness among healthcare providers and patients is encouraging the adoption of PIVKA II antigen testing, consequently increasing market demand and utilization.

4. Favorable Guidelines and Legislation: Favorable regulatory policies are aiding in the development and implementation of PIVKA II testing. This backing enhances the market and confidence in the technologies, hence fostering the adoption of new advancements.

5. Collaboration and Partnerships: Joint activities among educational institutions, industry, and healthcare sectors encourage the development of new PIVKA II products and their improved positioning in the market.

Challenges in the PIVKA II antigen market include:

1. High Testing Costs: The expenses related to performing PIVKA II testing can be prohibitive for some patients, limiting access to this service in specific populations and geographical areas.

2. Competition from Other Biomarkers: The existence of other liver cancer markers already in use could present competition for PIVKA II and highlight the need for persistent efforts to support its uniqueness.

3. Regulatory Hurdles in New Markets: Entering emerging markets may involve rigorous regulatory efforts that can delay the launch of PIVKA II testing solutions and limit market opportunities.

The interplay of all these drivers and challenges that positively affect the PIVKA II antigen market is evident. By exploiting opportunities and addressing problems, market participants can improve products and services and overall help advance the new standards of healthcare in liver disease management.

List of PIVKA II Antigen Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies PIVKA II antigen companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the PIVKA II antigen companies profiled in this report include-

• FUJIFILM
• LabCorp
• Abbexa
• GenScript
• Eisai

PIVKA II Antigen by Segment

The study includes a forecast for the global PIVKA II antigen market by type, application, and region.

PIVKA II Antigen Market by Type [Analysis by Value from 2019 to 2031]:

• Serum
• Plasma
• Others

PIVKA II Antigen Market by Application [Analysis by Value from 2019 to 2031]:

• Hospitals
• Clinics
• Others

PIVKA II Antigen Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the PIVKA II Antigen Market

The PIVKA II antigen market is evolving rather well as it is becoming a more essential biomarker in the diagnosis and follow-up of liver cancer. The market is evolving and increasing in opportunities and penetration due to technological advances in testing, increased awareness of liver diseases, and support from the governments of various regions, including the US, China, Germany, India, and Japan.

• United States: In the U.S., the PIVKA II biomarker has shown particularly promising clinical studies for hepatocellular carcinoma (HCC) patients. This has triggered regulatory agents to consider PIVKA II testing for integration into the normal treatment processes. The increasing partnership among biotechnology companies is bringing in new developments in analysis techniques, which improve the procedures used for diagnosing diseases early.
• China: Due to the increasing prevalence of liver diseases in China and the better availability of related healthcare services, the demand for PIVKA II antigen testing is increasing rapidly. New local firms are introducing various test kits as the necessity for the kits rises. Additionally, increasing efforts from the government to raise cancer awareness are helping to boost the usage of PIVKA II as a diagnostic method.
• Germany: Germany remains a significant market for the PIVKA II antigen and emphasizes research and development (R&D) and keen technological advancements in the laboratory. Recently, improvements made in laboratory technology have increased the efficiency of PIVKA II assays. Collaborative partnerships between the academic and healthcare fields are also making it easier to implement these tests.
• India: In India, the PIVKA II antigen market is also on an upswing due to the growing awareness of liver cancer. There is a trend among healthcare providers to use PIVKA II tests as part of evaluations for patients with liver disease. Further initiatives aimed at reducing the cost of such examinations are also assisting in broader adoption, which, in turn, improves the chances of timely diagnosis.
• Japan: The use of PIVKA II antigen testing incorporates the Japanese approach to healthcare, and relevant studies have advocated for its use ineffective liver cancer diagnosis. The state encourages revolutionary activities, especially in diagnostics, and partnerships between medical bodies and industries are yielding advanced solutions that strengthen the market.

Features of the Global PIVKA II Antigen Market

Market Size Estimates: PIVKA II antigen market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: PIVKA II antigen market size by type, application, and region in terms of value ($B).

Regional Analysis: PIVKA II antigen market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the PIVKA II antigen market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the PIVKA II antigen market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the PIVKA II antigen market by type (serum, plasma, and others), application (hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global PIVKA II Antigen Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global PIVKA II Antigen Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global PIVKA II Antigen Market by Type
  • 3.3.1: Serum
  • 3.3.2: Plasma
  • 3.3.3: Others
• 3.4: Global PIVKA II Antigen Market by Application
  • 3.4.1: Hospitals
  • 3.4.2: Clinics
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global PIVKA II Antigen Market by Region
• 4.2: North American PIVKA II Antigen Market
  • 4.2.1: North American Market by Type: Serum, Plasma, and Others
  • 4.2.2: North American Market by Application: Hospitals, Clinics, and Others
• 4.3: European PIVKA II Antigen Market
  • 4.3.1: European Market by Type: Serum, Plasma, and Others
  • 4.3.2: European Market by Application: Hospitals, Clinics, and Others
• 4.4: APAC PIVKA II Antigen Market
  • 4.4.1: APAC Market by Type: Serum, Plasma, and Others
  • 4.4.2: APAC Market by Application: Hospitals, Clinics, and Others
• 4.5: ROW PIVKA II Antigen Market
  • 4.5.1: ROW Market by Type: Serum, Plasma, and Others
  • 4.5.2: ROW Market by Application: Hospitals, Clinics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global PIVKA II Antigen Market by Type
  • 6.1.2: Growth Opportunities for the Global PIVKA II Antigen Market by Application
  • 6.1.3: Growth Opportunities for the Global PIVKA II Antigen Market by Region
• 6.2: Emerging Trends in the Global PIVKA II Antigen Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global PIVKA II Antigen Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global PIVKA II Antigen Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: FUJIFILM
• 7.2: LabCorp
• 7.3: Abbexa
• 7.4: GenScript
• 7.5: Eisai